Ann Arbor, MI – October 31st, 2024 – Genomenon, Inc., a leading provider of genomic intelligence solutions, today announced a major expansion to its Cancer Knowledgebase (CKB), a dynamic digital resource for interpreting even the most complex cancer genomic profiles, with the addition of clinical trials across 25 new countries in Europe.
CKB, previously Clinical Knowledgebase, is the go-to resource for thousands of clinicians and researchers globally. It saves time and uncovers valuable connections between cancer variants, therapies, and clinical trials. This expansion increases CKB's global coverage to 39 countries.
"The addition of these European clinical trials to CKB is a game-changer for clinicians and researchers worldwide," said Mike Klein, CEO of Genomenon. "By providing unparalleled access to global clinical trials, we're enabling clinicians to connect patients with targeted treatment options that can significantly improve outcomes."
The incorporation of European clinical trials addresses a critical need for users seeking trials in these regions. This development can potentially transform treatment outcomes by connecting patients with nearby clinical trials tailored to their genomic profile.
Genomenon's CKB offers multiple access options, including CKB CORE, the free-to-use platform encompassing 50 cancer-related genes, updated quarterly with a focus on specific themes, CKB BOOST, A web-based, subscription version including over 2000 cancer-related genes and CKB FLEX, a downloadable version delivering CKB content as flat files or JSON, facilitating seamless integration. Genomenon acquired CKB from The Jackson Laboratory (JAX) in May of 2024.
Genomenon will showcase CKB's enhanced capabilities at the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo, November 19-23, 2024, in Vancouver, British Columbia, Canada. Visit booth #1233 to learn more about CKB and attend its corporate workshop and scientific posters during the expo.
Media Contact:
The Real-world Evidence to validate a drug target, identify trial-eligible patients, or change a diagnosis already exists. It is buried in 39 million biomedical articles, locked behind paywalls and supplemental files most researchers never find.
Genomenon closes that gap. Fit-for-purpose AI-powered search reads 11.2 million full-text papers and 3.7 million supplemental datasets. Eighty expert scientific curators validate every finding. The result is structured, traceable, regulatory-grade Real-World Evidence at the genetic variant and patient level. Loxo@Lilly used Genomenon to add 73 variants to the RET label. In a head-to-head, Genomenon identified 83% more rare disease patients than ChatGPT plus OpenEvidence.
250+ diagnostic labs and 75 biopharma programs rely on Genomenon as the evidence layer behind precision medicine.
